Efficacy and Safety of Mirikizumab (LY3074828) in a Phase 2 Study of Patients with Crohn's Disease

(1) Mount Sinai Hospital,New York,United States

(2) University California San Diego,La Jolla,United States

(3) Nancy University Hospital,Vandoeuvre-les-Nancy,France

(4) Michigan Medicine Gastroenterology Clinic,Ann Arbor,United States

(5) Fukuoka University,Fukuoka,Japan

(6) Eli Lilly & Company,Indianapolis,United States

(7) Eli Lilly & Company,San Diego,United States

(8) Kitasato Institute Hospital Center for Advanced IBD Research and Treatment,Tokyo,Japan

This item was part of the Randomised controlled trials in IBD II session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019